LEXICON PHARMACEUTICALS, INC.
LXRX evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $834.3M
- Lead Asset:
- inpefa (Approved)
What it means
What to watch
Prepared research question
What matters most for LXRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LXRX
LEXICON PHARMACEUTICALS, INC. (LXRX) is a biopharmaceutical company focused on developing and commercializing small-molecule drug candidates, with its most advanced program being sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, and a pipeline including pilavapadin for neuropathic pain and LX9851 for obesity.
Key risk: Cash runway limited
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial · 1 catalyst for LEXICON PHARMACEUTICALS, INC..
LEXICON PHARMACEUTICALS, INC. (LXRX) is a biopharmaceutical company focused on developing and commercializing small-molecule drug candidates, with its most advanced program being sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, and a pipeline including pilavapadin for neuropathic pain and LX9851 for obesity.
- Completed patient enrollment in the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin for hypertrophic cardiomyopathy [sec_mda · as of 2026-08-06].
- Pursuing regulatory approval of ZYNQUISTA (sotagliflozin) for type 1 diabetes, with NDA resubmission anticipated mid-2026 [news · published 2026-05-07].
- Reported positive Phase 2 results for pilavapadin in diabetic peripheral neuropathic pain and received FDA Fast Track designation [sec_mda · as of 2026-08-06].
- Cash and equivalents of $40.9M as of 2026-06-30, with total revenue of $0.7M and net income of -$31.8M for the period [latest reported financials].
- Novo Nordisk initiated clinical development of LX9851, an obesity drug candidate [news · published 2026-05-07].
What works
- Sotagliflozin has a fully enrolled Phase 3 trial (SONATA-HCM) with a defined data readout in 1Q27, providing a near-term catalyst [news · published 2026-10-02].
- Pilavapadin has shown clear evidence of effect in Phase 2b and received FDA Fast Track designation, indicating regulatory interest [sec_mda · as of 2026-08-06].
- The company has secured a $100 million loan facility and capital raises, reinforcing its financial position [news · published 2026-05-07].
- Novo Nordisk's initiation of LX9851 development suggests external validation of the asset's potential [news · published 2026-05-07].
What to weigh
- The company reported a net loss of $31.8M for the period ending 2026-06-30, with minimal revenue of $0.7M [latest reported financials].
- Cash and equivalents of $40.9M as of 2026-06-30 may be limited given substantial future capital requirements for R&D and regulatory approvals [sec_mda · as of 2026-08-06].
- The company faces a $5 million milestone payment to Bristol-Myers Squibb upon dosing the first patient in a Phase 3 trial of pilavapadin [sec_mda · as of 2026-08-06].
- Sotagliflozin's patent is set to expire in 2030, which could impact long-term revenue if approved [upcoming catalysts].
From the filings
Quoted directly from source documents.
SONATA-HCM Phase 3 trial fully enrolled
“completed patient enrollment in our SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication”
SEC MD&A · August 6, 2026
Pilavapadin Phase 2b results showed clear evidence of effect
“demonstrated clear evidence of effect at the 10 mg dose”
SEC filings · August 6, 2026
Catalyst timeline
- 2030-10-07 · Patent_Expiry · SOTAGLIFLOZIN — Patent expiry for NDA216203 (sotagliflozin) may affect market exclusivity if the drug is approved.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $40.9M as of 2026-06-30 may be insufficient given ongoing R&D costs and milestone payments [latest reported financials].
- Regulatory approval uncertainty — ZYNQUISTA NDA resubmission for type 1 diabetes faces FDA review risk [news · published 2026-05-07].
- Patent expiry for sotagliflozin — Sotagliflozin patent expires in 2030, potentially limiting exclusivity if approved [upcoming catalysts].
- Milestone payment obligation — $5M milestone due to Bristol-Myers Squibb upon Phase 3 start of pilavapadin [sec_mda · as of 2026-08-06].
What to watch
- Data readout from the SONATA-HCM Phase 3 trial in 1Q27 [news · published 2026-10-02].
- FDA decision on ZYNQUISTA NDA resubmission for type 1 diabetes, anticipated mid-2026 [news · published 2026-05-07].
- Progress of third-party collaboration discussions for pilavapadin [sec_mda · as of 2026-08-06].
- Novo Nordisk's clinical development of LX9851 [news · published 2026-05-07].
Sources: News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run LEXICON PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LEXICON PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.43 · 0% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~1454d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
136
Total value held
$502.1M
| Holder | Shares | Value |
|---|---|---|
| artal group s.a. | 154,734,327 | $241.4M |
| fmr llc | 45,056,338 | $70.3M |
| siren, l.l.c. | 44,303,518 | $69.1M |
| sessa capital im, l.p. | 17,912,961 | $27.9M |
| vanguard capital management llc | 9,519,167 | $14.8M |
| point72 asset management, l.p. | 7,814,606 | $12.2M |
| millennium management llc | 4,944,731 | $7.7M |
| blackrock, inc. | 3,322,219 | $5.2M |
| geode capital management, llc | 3,169,111 | $4.9M |
| jane street group, llc | 2,665,938 | $4.2M |
Showing top 10 of 136 institutional holders of LEXICON PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 10.7%
- Days to cover
- 8.6
- Shares short
- 22,932,295
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LXRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for LEXICON PHARMACEUTICALS, INC.?
LEXICON PHARMACEUTICALS, INC. (LXRX) is a biopharmaceutical company focused on developing and commercializing small-molecule drug candidates, with its most advanced program being sotagliflozin for hypertrophic cardiomyopathy and type 1 diabetes, and a pipeline including pilavapadin for neuropathic pain and LX9851 for obesity.
What is LEXICON PHARMACEUTICALS, INC.'s lead drug candidate?
LEXICON PHARMACEUTICALS, INC.'s most advanced tracked candidate is inpefa (Approved) for heart failure, type 2 diabetes mellitus, chronic kidney disease (CKD).
What is LEXICON PHARMACEUTICALS, INC.'s next catalyst?
LEXICON PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA216203" — expected October 7, 2030.
Who is the CEO of LEXICON PHARMACEUTICALS, INC.?
Dr. Michael S. Exton Ph.D. is the chief executive officer of LEXICON PHARMACEUTICALS, INC. (LXRX).
Where is LEXICON PHARMACEUTICALS, INC. headquartered?
LEXICON PHARMACEUTICALS, INC. (LXRX) is headquartered in The Woodlands, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.